Chronic inflammatory demyelinating polyradiculoneuropathy: Update on clinical features, phenotypes and treatment options

Current Opinion in Neurology

Volumn 26, Issue 5, 2013, Pages 496-502

  Eftimov, Filip ^a   Van Schaik, Ivo ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DEMYELINATING NEUROPATHY; DISEASE COURSE; DISTAL PARESTHESIA; EVOKED SOMATOSENSORY RESPONSE; FATIGUE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOMODULATION; LUMBOSACRAL PLEXUS; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MOTOR NERVE CONDUCTION; MOTOR NEUROPATHY; NERVE CONDUCTION; OUTCOME ASSESSMENT; PAIN; PHENOTYPE; POLYRADICULONEUROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RESTLESS LEGS SYNDROME; REVIEW; TREATMENT RESPONSE; TREMOR;

HUMANS; IMMUNOGLOBULINS; NEUROLOGIC EXAMINATION; PHENOTYPE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TIME; TREATMENT OUTCOME;

EID: 84883760449     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328363bfa4     Document Type: Review

References (59)

1. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society: First revision. Eur J Neurol 2010; 17:356-363.
2. van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011; 76:337-345.
3. Vanhoutte EK, Faber CG, van Nes SI, et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 2012; 135:1639-1649.
4. Bril V, Banach M, Dalakas MC, et al. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 2010; 42:492-497.
5. Rajabally YA, Narasimhan M. Distribution, clinical correlates and significance of axonal loss and demyelination in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 2011; 18:293-299.
6. Lin CS, Krishnan AV, Park SB, Kiernan MC. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2011; 68:862-869.
7. Mausberg AK, Dorok M, Stettner M, et al. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology 2013; 80:296-303.
8. Schneider-Hohendorf T, Schwab N, Uceyler N, et al. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78:402-408.
9. Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: An epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78:1349-1353.
10. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010; 15: 50-56.
11. van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): A double-blind, randomised, controlled trial. Lancet Neurol 2010; 9:245-253.
12. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: A randomised controlled trial. Lancet Neurol 2012; 11:493-502.
13. Maisonobe T, Chassande B, Verin M, et al. Chronic dysimmune demyelinating polyneuropathy: A clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry 1996; 61:36-42.
14. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48:321-328.
15. Rajabally YA, Simpson BS, Beri S, et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: Study of a UK population. Muscle Nerve 2009; 39:432-438.
16. Gorson KC, van Schaik IN, Merkies IS, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: Recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010; 15:326-333.
17. Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol 2003; 250:714-724.
18. Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 2010; 41:202-207.
19. Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: A prospective study. Neurology 2010; 74:1680-1686.
20. McMillan HJ, Kang PB, Jones HR, Darras BT. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: Combined analysis of a large cohort and eleven published series. Neuromuscul Disord 2013; 23:103-111.
21. Boukhris S, Magy L, Gallouedec G, et al. Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: A study of 11 cases. J Peripher Nerv Syst 2005; 10:329-337.
22. Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 2009; 14:310-315.
23. Goebel A, Lecky B, Smith LJ, Lunn MP. Pain intensity and distribution in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012; 46:294-295.
24. Straver DC, van den Berg LH, Franssen H. Activity-dependent conduction block in chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2011; 300:33-38.
25. Saifee TA, Schwingenschuh P, Reilly MM, et al. Tremor in inflammatory neuropathies. J Neurol Neurosurg Psychiatry 2012. [Epub ahead of print]
26. Rajabally YA, Shah RS. Restless legs syndrome in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2010; 42:252-256.
27. Figueroa JJ, Dyck PJ, Laughlin RS, et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78:702-708.
28. Eftimov F, Vermeulen M, van Doorn PA, et al. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012; 78:1079-1084.
29. Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67:802-807.
30. Kuitwaard K, van den Berg LH, Vermeulen M, et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010; 81:1374-1379.
31. Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013; 20:836-842.
32. Cocito D, Grimaldi S, Paolasso I, et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol 2011; 18:1417-1421.
33. Hughes RA, Gorson KC, Cros D, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74:651-657.
34. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle Nerve 2007; 35:66-69.
35. Mahdi-Rogers M, Rutterford C, Hughes RA, et al., RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): A pilot, multicentre study. Lancet Neurol 2009; 8:158-164.
36. Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry 2010; 81:634-636.
37. Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIGdependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257:913-919.
38. Mathis S, Magy L, Diallo L, et al. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012; 45:26-31.
39. Benedetti L, Briani C, Franciotta D, et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: A report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82:306-308.
40. Larue S, Bombelli F, Viala K, et al. Nonanti-MAG DADS neuropathy as a variant of CIDP: Clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011; 18:899-905.
41. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54:615-620.
42. Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: An under-recognized entity?. Muscle Nerve 2013. [epub ahead of print]
43. Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: Chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992; 55:677-680.
44. Sinnreich M, Klein CJ, Daube JR, et al. Chronic immune sensory polyradiculopathy: A possibly treatable sensory ataxia. Neurology 2004; 63:1662-1669.
45. Sabatelli M, Madia F, Mignogna T, et al. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol 2001; 248:772-777.
46. Kimura A, Sakurai T, Koumura A, et al. Motor-dominant chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257:621-629.
47. Niermeijer JM, Fischer K, Eurelings M, et al. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: A prospective cohort study. Neurology 2010; 74:406-412.
48. Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol 2003; 60:260-264.
49. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM antimyelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009; 65:286-293.
50. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2012; 5:CD002827.
51. Léger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM antimyelin-associated glycoprotein neuropathy. Neurology 2013; 80:2217-2225.
52. Viala K, Renie L, Maisonobe T, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004; 127:2010-2017.
53. Gorson KC, Ropper AH, Weinberg DH. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 1999; 22:758-765.
54. Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: The Lewis-Sumner syndrome. Muscle Nerve 1999; 22:560-566.
55. Attarian S, Verschueren A, Franques J, et al. Response to treatment in patients with Lewis-Sumner syndrome. Muscle Nerve 2011; 44:179-184.
56. Rajabally YA, Chavada G. Lewis-Sumner syndrome of pure upper-limb onset: Diagnostic, prognostic, and therapeutic features. Muscle Nerve 2009; 39:206-220.
57. Oh SJ, Claussen GC, Kim DS. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): A separate entity or a variant of chronic inflammatory demyelinating polyneuropathy?. J Peripher Nerv Syst 1997; 2:362-369.
58. Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating neuropathy. Brain 1996; 119 (Pt 3):765-774.
59. Ayrignac X, Rodrigues BS, Morales R, et al. Focal CIDP presenting as chronic progressive monomelic sensory neuropathy. Muscle Nerve 2013; 47:143-144.